Trial Profile

Phase 1 study of TraceNETTM in neuroendocrine tumours patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jul 2025 According to Angelini Group media release, the company has co-led a CHF79 million Series B financing round in NUCLIDIUM, which will fund the clinical development of NUCLIDIUM's Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications.
29 Mar 2023 New trial record
21 Mar 2023 According to a Trophic Communications media release, Prof. Melpomeni Fani is the principal investigator for this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com